Wang L, Wen X, Luan F, et al. - Researchers assessed the clinical value and mechanism of EIF3B, a core subunit of the EIF (eukaryotic translation initiation factor) 3 family, in the progression of gastric cancer (GC). They analyzed 78 GC tissue samples using quantitative PCR and 94 GC tissue samples using immunohistochemistry staining to determine EIF3B expression. In vitro and in vivo assays were used to determine the role of EIF3B in GC progression. A poorer 5-year survival was reported in GC patients with high EIF3B expression in multivariate analysis. Depth of tumor invasion, lymph node metastasis and TNM stage were significantly linked to high expression of EIF3B. GC cell proliferation was promoted by EIF3B; a strong link with proliferating cell nuclear antigen expression in GC samples was shown by EIF3B. As a result of knockdown of EIF3B in GC cells, suppression of the growth of xenograft tumors and lung metastatic colonization in vivo were seen. The activation of PI3K/AKT/mTOR signaling pathway by EIF3B was shown by gene set enrichment analysis and Western blot findings. Overall, an oncogenic role of EIF3B in GC progression was shown, and EIF3B was identified as an independent prognostic factor for GC patients.